Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.

The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research. Bone Biologics has been developing NELL-1-based products, including bone graft substitutes intended for use with spinal fusion procedures. The company’s strategy is to combine its biologic technology with established scaffold materials and delivery systems to create products designed to promote bone regeneration.

Bone Biologics has historically operated as a development-stage biotechnology company and has focused its research and commercialization efforts primarily on the United States spine and orthopedic markets. Its products remain subject to clinical development and regulatory approval, and the company has not established a broad portfolio of commercially marketed products based on the available information.

Key Stats

• Today's Range: $0.46 to $0.49
• 50-Day Range: $0.47 to $0.98
• 52-Week Range: $0.43 to $2.76
• Volume: 36,265 shs
• Average Volume: 301,005 shs
• Market Capitalization: $1.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Bone Biologics Stock Analysis - MarketRank™

Bone Biologics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Bone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bone Biologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bone Biologics are expected to grow in the coming year, from ($1.23) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bone Biologics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bone Biologics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bone Biologics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.89% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently increased by 38.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bone Biologics does not currently pay a dividend.

Dividend Growth

Bone Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Bone Biologics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for BBLG on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.00% of the stock of Bone Biologics is held by insiders.

Percentage Held by Institutions

34.30% of the stock of Bone Biologics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BBLG
• Previous Symbol: NASDAQ:BBLG
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.87%
• Return on Assets: -53.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.67
• Quick Ratio: 8.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.00 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 2,760,000
• Free Float: 2,618,000
• Market Cap: $1.29 million
• Optionable: Not Optionable
• Beta: 0.90